Deciphera reports data from GIST cohort of Phase I trial of DCC-2618

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported data from 57 evaluable heavily pretreated patients with gastrointestinal stromal tumors (GIST) in a Phase I trial to treat advanced malignancies showing that once-daily oral DCC-2618 at doses of ≥100 mg led to 12- and 24-week disease control rates (DCR) of 76% and 57%, respectively. Data were presented at the European Society for Medical Oncology meeting in Madrid and at the Connective Tissue Oncology Society meeting in Maui.

The company said the data support both the selection of a once-daily 150 mg dose of DCC-2618 as the recommended dose and a Phase III trial in patients with GIST...